Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts
Authors
Keywords
-
Journal
Nature Communications
Volume 11, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-04-24
DOI
10.1038/s41467-020-15885-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Patient-Derived Xenograft Models in Urological Malignancies: Urothelial Cell Carcinoma and Renal Cell Carcinoma
- (2020) Andrew T. Tracey et al. Cancers
- HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers
- (2020) Bob T. Li et al. Cancer Discovery
- Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
- (2019) Yohann Loriot et al. NEW ENGLAND JOURNAL OF MEDICINE
- Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling
- (2019) Brian D. Robinson et al. Nature Communications
- A Consensus Molecular Classification of Muscle-invasive Bladder Cancer
- (2019) Aurélie Kamoun et al. EUROPEAN UROLOGY
- Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy
- (2019) Luca Zammataro et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cancer Susceptibility Mutations in Patients With Urothelial Malignancies
- (2019) Maria I. Carlo et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer
- (2018) Gopa Iyer et al. JOURNAL OF CLINICAL ONCOLOGY
- Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial
- (2018) Bob T. Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of Pathological Stage in Patients Treated with and without Neoadjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma
- (2018) Ross S. Liao et al. JOURNAL OF UROLOGY
- HER kinase inhibition in patients with HER2- and HER3-mutant cancers
- (2018) David M. Hyman et al. NATURE
- Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma
- (2018) François Audenet et al. CLINICAL CANCER RESEARCH
- Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma
- (2017) Tyler J. Moss et al. EUROPEAN UROLOGY
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- (2017) Ahmet Zehir et al. NATURE MEDICINE
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma
- (2016) Aditya Bagrodia et al. JOURNAL OF UROLOGY
- Clonal evolution of chemotherapy-resistant urothelial carcinoma
- (2016) Bishoy M Faltas et al. NATURE GENETICS
- RECQL4 Promotes DNA End Resection in Repair of DNA Double-Strand Breaks
- (2016) Huiming Lu et al. Cell Reports
- Genomic Characterization of Upper Tract Urothelial Carcinoma
- (2015) John P. Sfakianos et al. EUROPEAN UROLOGY
- Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
- (2015) Donavan T. Cheng et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Orchestrating high-throughput genomic analysis with Bioconductor
- (2015) Wolfgang Huber et al. NATURE METHODS
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies
- (2015) Wolfgang Jäger et al. Oncotarget
- Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy
- (2014) Woonyoung Choi et al. CANCER CELL
- The extracellular matrix modulates the hallmarks of cancer
- (2014) M. W. Pickup et al. EMBO REPORTS
- Picrosirius Red Staining
- (2014) Raed Lattouf et al. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
- Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine
- (2014) Eliezer M Van Allen et al. NATURE MEDICINE
- Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology
- (2014) J. S. Damrauer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Development and characterization of a bladder cancer xenograft model using patient-derived tumor tissue
- (2013) Bumsoo Park et al. CANCER SCIENCE
- Deciphering Signatures of Mutational Processes Operative in Human Cancer
- (2013) Ludmil B. Alexandrov et al. Cell Reports
- Current Preclinical Models for the Advancement of Translational Bladder Cancer Research
- (2012) D. J. DeGraff et al. MOLECULAR CANCER THERAPEUTICS
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- Second harmonic generation microscopy for quantitative analysis of collagen fibrillar structure
- (2012) Xiyi Chen et al. Nature Protocols
- RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
- (2011) Bo Li et al. BMC BIOINFORMATICS
- Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma
- (2010) Surena F. Matin et al. CANCER
- Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
- (2010) Daniel J. Sargent et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Genetic Predictors of MEK Dependence in Non-Small Cell Lung Cancer
- (2008) C. A. Pratilas et al. CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More